Accretion Pharmaceuticals Ltd
Accretion Pharmaceuticals Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #2 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Accretion Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Year-on-year increase in revenue: Rs. 1130.48 Lakhs (approx. 25.85% increase).
As stated in Accretion Pharmaceuticals Ltd's Q2 FY27 results statement · published 31 Oct 2026. Reported figures, not investment advice.
Based on Accretion Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for the half year ended 30th September 2026: Rs. EBITDA for the half year ended 30th September 2026: Rs.
From Accretion Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 31 Oct 2026.
Revenue & Sales Performance
Profitability & Margins
See what Accretion Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Accretion Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Accretion Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Accretion Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
What Accretion Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL
- Lyka Labs Ltd (Q2 FY27)
Year-on-Year revenue growth for the quarter: approximately 104.5% increase (8,650.89 vs 4,230.94 lakhs). Key results statement takeaways from Lyka Labs Ltd's Q2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- 2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Accretion Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Accretion Pharmaceuticals Ltd Q2 FY27 results?
Revenue from Operations for the half year ended 30th September 2026: Rs. EBITDA for the half year ended 30th September 2026: Rs.
What is Accretion Pharmaceuticals Ltd share price analysis?
Accretion Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 21.9 with a market cap of ₹212 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Accretion Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.